What does symproic and other — thereafter mean?

This metric represents the net product revenue generated by the company's secondary pharmaceutical portfolio, specifically including Symproic and related non-core assets. It serves as a measure of the commercial performance and market demand for these specific therapeutic products outside of the primary flagship offerings. Monitoring this revenue stream helps investors assess the diversification of the product mix and the contribution of secondary assets to the company's overall top-line growth.

Collegium Pharmaceutical, Inc. COLL Symproic and other — Thereafter

Other product segments

Jornay Pm

$104.78M-44.4%

Similar metrics at other companies

REGNOther products — Revenue

$31.3M—

OGNOther Biosimilars — Revenue

$24M+380%

VTRSProduct and Service, Other — Other revenues

$7.3M-34.2%

AMGNOther products — Total revenues

$1.53B+3.6%

VIROther revenue — Total revenues

$0-100%

ACLSOther Products Systems Services And Royalties — Revenue

$3.74M-11.1%

Other financials

Income statement

See full

Revenue$193.5M+8.9%

Gross profit$117.2M+20.5%

Operating income$30.9M+42.5%

Net income$14.5M+500%

EPS (diluted)$0.40+471%

Balance sheet

See full

Cash & equivalents$289.6M+147%

Total debt$5.2M-19.5%

Total equity$312.4M+33.3%

Total assets$1.7B+1.3%

Cash flow

See full

Operating cash flow$57.1M+3.1%

CapEx$270.0K-66.2%

Free cash flow$56.8M+4.1%

Valuation

See full

Market cap$1.15B+20.4%

Enterprise value$869.67M+2.5%

P/E15.4×-6.4×

P/S1.5×0.0×

Profitability

See full

Gross margin60.7%+3.0pp

Operating margin23.7%+2.3pp

Net margin9.4%+2.8pp

FCF margin41.4%+10.4pp

Returns & leverage

See full

Return on equity27.4%+8.2pp

Debt / equity0×0.0×

Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive.

The official record: Collegium Pharmaceutical, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic and other — thereafter.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s symproic and other — thereafter?: Collegium Pharmaceutical, Inc. (COLL) reported symproic and other — thereafter of $6.07M in Q4 2025.
What does symproic and other — thereafter mean?: This metric represents the net product revenue generated by the company's secondary pharmaceutical portfolio, specifically including Symproic and related non-core assets. It serves as a measure of the commercial performance and market demand for these specific therapeutic products outside of the primary flagship offerings. Monitoring this revenue stream helps investors assess the diversification of the product mix and the contribution of secondary assets to the company's overall top-line growth.